Caroline's Feed
Jan 23, 2013

WellPoint profit beats, but 2013 outlook “prudent”

By Caroline Humer

(Reuters) – WellPoint Inc (WLP.N: Quote, Profile, Research, Stock Buzz) reported a higher-than-expected fourth-quarter profit on Wednesday, but the second-largest U.S. health insurer said it was taking a “prudent” view of 2013 as it faces industry reform.

WellPoint, which sells private health insurance to businesses and individuals and also provides government insurance for the elderly and the poor, is preparing for a round of changes resulting from the U.S. Affordable Care Act.

Jan 17, 2013

UnitedHealth Q4 revenue rises as costs kept in check

By Caroline Humer

(Reuters) – UnitedHealth Group Inc (UNH.N: Quote, Profile, Research), the largest U.S. health insurer, said on Thursday it kept fourth-quarter costs under control and increased revenue by more than 11 percent, helping earnings per share to rise.

The company, which provides health care benefits through both employer and government-paid insurance plans and serves individuals and military members, also backed its forecast for 2013 revenue growth of at least 11 percent and said earnings would be in a range of slightly down to up 4 percent.

Jan 17, 2013

UnitedHealth says fourth-quarter costs were low and revenue rose

By Caroline Humer

(Reuters) – UnitedHealth Group Inc (UNH.N: Quote, Profile, Research, Stock Buzz), the largest U.S. health insurer, said on Thursday that it kept fourth-quarter 2012 costs under control and increased revenue by more 11 percent, helping earnings per share rise.

The company, which provides health care benefits through both employer and government paid insurance plans and serves the individual and military markets, also backed its forecast for at least 11 percent 2013 revenue growth and said earnings would be in a range of slightly down to up 4 percent.

Jan 17, 2013

UnitedHealth says Q4 costs were low and revenue rose

Jan 17 (Reuters) – UnitedHealth Group Inc, the
largest U.S. health insurer, said on Thursday that it kept
fourth-quarter 2012 costs under control and increased revenue by
more 11 percent, helping earnings per share rise.

The company, which provides health care benefits through
both employer and government paid insurance plans and serves the
individual and military markets, also backed its forecast for at
least 11 percent 2013 revenue growth and said earnings would be
in a range of slightly down to up 4 percent.

Jan 11, 2013

U.S. faces shortages of flu vaccine, Tamiflu treatment

By Ransdell Pierson and Caroline Humer

(Reuters) – One of the worst U.S. flu seasons in a decade has created shortages of vaccine and the Tamiflu treatment for children, raising the prospect that people considered at high risk of getting the flu might not get the protection they need.

Though shortages are not unusual, the flu’s early arrival and this year’s especially nasty strain mean the situation could worsen.

Jan 10, 2013

Drugmakers report U.S. shortages of flu vaccine, Tamiflu

Jan 10 (Reuters) – This year’s early and potentially severe
flu season has created shortages of the children’s formulation
of the leading treatment and most forms of the top-selling flu
vaccine in the United States, according to their manufacturers.

Roche Holding AG told Reuters late on Wednesday
that it had a shortage of the liquid formulation of Tamiflu,
which is used mainly to slow down or stop the symptoms of the
flu in children already infected with the virus.

Jan 4, 2013

Eli Lilly banks on cost controls for higher 2013 profit

By Bill Berkrot and Caroline Humer

(Reuters) – Eli Lilly and Co said on Friday it expects profit in 2013 to increase by more than Wall Street had been forecasting, primarily due to cost controls and improved productivity.

Lilly, whose shares were up nearly 4 percent on Friday, said 2013 sales will be flat to a bit higher, despite the loss of patent on its $5 billion-a-year antidepressant, Cymbalta, in December.

Dec 31, 2012

FDA new drug approvals hit 16-year high in 2012

LONDON/NEW YORK (Reuters) – U.S. regulators approved 39 new drugs in 2012, the most in 16 years, suggesting that pharmaceutical makers are poised for growth after losing billions of dollars in recent years to generic drug makers because of patent expirations.

There were eight approvals in December alone, including a new treatment from Johnson & Johnson called Sirturo for drug-resistant tuberculosis approved on Monday, the first new TB drug in decades.

Dec 12, 2012

Aetna to join 15 exchanges under U.S. healthcare reform

NEW YORK, Dec 12 (Reuters) – Aetna Inc, the third
largest U.S. health insurer, said on Wednesday that by 2014 it
expects to be part of about 15 healthcare exchanges being
established under government reforms.

Aetna, one of the companies on the front lines of healthcare
changes in the United States, told analysts and investors it
believes an increase in customers from the new market places
would likely contribute to its growth.

Dec 12, 2012

Aetna plans to join 15 exchanges under U.S. healthcare reform

NEW YORK, Dec 12 (Reuters) – Aetna Inc, the third
largest U.S. health insurer, said on Wednesday that by 2014 it
expects to be part of about 15 healthcare exchanges being
established under government reforms.

Aetna, one of the companies on the front lines of healthcare
changes in the United States, told analysts and investors that
it believes an increase in the number of customers from the new
market places will likely contribute to its growth.